- Free from Publisher SJ McNulty, E Ur, G Williams - Diabetes Care, 2003 - Am Diabetes Assoc RESULTS—Sibutramine induced significant weight loss (P < 0.001) with both 15
mg/day (5.5 ± 0.6 kg at 12 months) and 20 mg/day (8.0 ± 0.9 kg), whereas
placebo did not (0.2 ± 0.5 kg). Weight loss ≥10% was achieved by 14 and ... Cited by 98 - Related articles - BL Direct - All 6 versions
- Free from Publisher JM Miles, L Leiter, P Hollander, T Wadden, JW … - Diabetes Care, 2002 - Am Diabetes Assoc RESULTS—After 1 year of treatment, mean (±SE) weight loss was greater in the
orlistat than in the placebo group (−4.6 ± 0.3% vs. −1.7 ± 0.3% of
baseline wt, P < 0.001). Orlistat treatment caused a greater improvement in ... Cited by 171 - Related articles - BL Direct - All 7 versions
M Serrano-Rios, N Melchionda, E Moreno- … - Diabetic Medicine, 2002 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 51 - Related articles - BL Direct - All 4 versions
L Sánchez-Reyes, G Fanghänel, J Yamamoto, … - Clinical therapeutics, 2004 - Elsevier The management of type 2 diabetes mellitus is complicated by the presence of
risk factors related to overweight and obesity, particularly visceral adiposity.
However, weight loss and weight maintenance are difficult for patients with ... Cited by 27 - Related articles - All 3 versions
- Free from Publisher DE Kelley, GA Bray, FX Pi-Sunyer, S Klein, J … - Diabetes Care, 2002 - Am Diabetes Assoc OBJECTIVE—Weight loss improves glycemic control, lipid profiles, and blood
pressure in patients with type 2 diabetes. However, successful long-term weight
loss is difficult for these patients, particularly those treated with ... Cited by 172 - Related articles - BL Direct - All 7 versions
H Hauner, M Meier, G Wendland, T Kurscheid … - Experimental and clinical endocrinology & diabetes, 2004 - cat.inist.fr Background: Sibutramine is a selective serotonin and noradrenaline reuptake
inhibitor that is known to reduce body weight. The efficacy of this drug in
primary care medicine is currently unknown. Objective: To study, in a ... Cited by 52 - Related articles - BL Direct - All 2 versions
K Fujioka, TB Seaton, E Rowe, CA Jelinek, P … - Diabetes, Obesity and Metabolism, 2000 - ingentaconnect.com Weight loss with sibutramine improves glycaemic control and ... K. Fujioka, 1
TB Seaton, 2 E. Rowe, 2 CA Jelinek, 2 P. Raskin, 3 HE Lebovitz, 4 ... SP
Weinstein 2 and the Sibutramine/Diabetes Clinical Study Group* Cited by 137 - Related articles - BL Direct - All 4 versions
IG Smith, MA Goulder… - Journal of Family Practice, 2001 - grande.nal.usda.gov Record Detail. Return to previous page, Save: Title: Randomized placebo-controlled
trial of long-term treatment with sibutramine in mild to moderate obesity. ... Cited by 120 - Related articles - Cached - BL Direct - All 3 versions
SH Kim, YM Lee, SH Jee, CM Nam - Obesity, 2003 - nature.com Results: The effect size of sibutramine on weight change was -1.00 (-1.17 to
-0.84), whereas the effect sizes on SBP and DBP changes were 0.16 (0.08 to 0.24)
and 0.26 (0.18 to 0.33), respectively. By subgroup analysis, the effect ... Cited by 56 - Related articles - BL Direct - All 3 versions
- Free from Publisher A Gokcel, H Karakose, EM Ertorer, N Tanaci, … - Diabetes Care, 2001 - Am Diabetes Assoc RESULTS—One patient in the sibutramine group was excluded during the study
period because of hypertension; thus, a total of 29 data sets were analyzed for
this group. In the placebo group, five patients had to be excluded because ... Cited by 81 - Related articles - BL Direct - All 5 versions
